Yahoo Finance

Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for suprachoroidal delivery

PARIS, France – 14 November 2025: Coave Therapeutics (“Coave”), a company redefining targeted gene therapy with a best-in-class pipeline powered by ligand-conjugated vectors, today announces the ...
Nature

Systemic delivery of IL-10 by an AAV vector prevents vascular remodeling and end-organ damage in stroke-prone spontaneously hypertensive rat

Interleukin-10 (IL-10) ameliorates various T-helper type 1 cell-mediated chronic inflammatory diseases. Although the therapeutic benefits of IL-10 include antiatherosclerotic effects, ...
Nature

The myeloid-binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting

All mice were of C57BL/6J background and 7–14 weeks of age. Mice were obtained from Jackson Laboratory (Bar Harbor, ME, USA) or through breeding in authors’ animal facility. Experimental procedures ...
Business Insider

Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for suprachoroidal delivery

Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for suprachoroidal delivery CoTx-101 represents a potential breakthrough for ...
manilatimes

Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for suprachoroidal delivery

Powered by Coave's first-in-class proprietary suprachoroidal vector (coAAV-SCS), CoTx-101 represents a potential breakthrough treatment for retinal vascular diseases, combining the three essential ...